Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DW5UI2
|
|||
| Drug Name |
CTI-1601
|
|||
| Drug Type |
Recombinant protein
|
|||
| Indication | Friedreich's ataxia [ICD-11: 8A03.10; ICD-9: 334] | Phase 2 | [1] | |
| Company |
Larimar Therapeutics Bala Cynwyd, PA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Soluble guanylate cyclase (GCS) | Target Info | Stimulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05579691) A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Exploration Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CTI-1601 in Adult Subjects With Friedreich's Ataxia. U.S.National Institutes of Health. | |||
| REF 2 | The CNS-Penetrant Soluble Guanylate Cyclase Stimulator CY6463 Reveals its Therapeutic Potential in Neurodegenerative Diseases. Front Pharmacol. 2021 May 24;12:656561. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.